CollabRx (CLRX) and OncoDNA Partner in Molecular Diagnostics

SAN FRANCISCO, April 4, 2013 (GLOBE NEWSWIRE) — CollabRx, Inc. (Nasdaq:CLRX), a data analytics company focused on informing clinical decision making in molecular medicine, and OncoDNA, SA, a Belgium company that provides DNA next generation sequencing (NGS) tests for clinical use in cancer, today announced a multi-year agreement to purchase CollabRx SaaS-based technology and content resources to be used in conjunction with OncoDNA’s cancer mutation panels.

OncoDNA and CollabRx will develop a combined test and medical informatics solution by pairing the results of cancer mutational panels developed by OncoDNA with clinically actionable and dynamically updated knowledge provided by CollabRx. Such knowledge includes the clinical impact of specific mutational profiles and associated therapeutic strategies such as drugs and clinical trials and is supported by CollabRx’s large and growing network of over 75 leading clinical practitioners in the U.S. and Europe.

“NGS-based tests are increasingly becoming a routine part of clinical care for cancer patients, but the complexity of the genetic data from tumor mutations is outpacing the ability of physicians to stay current with advanced treatments,” said Jean-Pol Detiffe, Founder & CEO of OncoDNA. “We are excited to partner with CollabRx to close this knowledge gap and enable physicians who order OncoDNA tests to access highly credible knowledge provided by CollabRx to aid in the interpretation of test results.”

The partnership, CollabRx’s first outside the United States, will leverage the company’s semantic integration platform, a proprietary technology that enables CollabRx scientists and physicians to dynamically update the company’s molecular oncology knowledge base with the latest medical and scientific data available in the public domain.

“Our agreement with OncoDNA reflects our commitment to partner with best-in-class laboratories and diagnostic companies and is a significant step forward in our strategy to serve high-growth markets outside of the U.S.,” said Thomas Mika, Chairman, President & CEO of CollabRx. “We are excited to work with OncoDNA to establish a leadership position in the clinical next generation sequencing market in Europe by providing ordering physicians with clinically relevant interpretation of test results as a seamless part of the reporting process.”

The OncoDNA partnership demonstrates CollabRx’s accelerating pace of business, product and channel development in 2013. This new milestone attests to the growing adoption of CollabRx technology and interpretive analytics in top-tier laboratories worldwide as a standard aspect of test reporting for clinical cancer sequencing.

About CollabRx

CollabRx, Inc. (Nasdaq:CLRX) is a recognized leader in cloud-based expert systems to inform healthcare decision-making. CollabRx uses information technology to aggregate and contextualize the world’s knowledge on genomics-based medicine with specific insights from the nation’s top cancer experts, starting with the area of greatest need: advanced cancers in patients who have effectively exhausted the standard of care. More information may be obtained at http://www.collabrx.com.

About OncoDNA

Through its founders, OncoDNA has over 60 years’ expertise in medical diagnostics and was founded by a team of experts with many years’ experience in DNA sequencing and diagnostic analyses in oncology. More information can be obtained at http://www.oncodna.com.

CollabRx Safe Harbor Statement

This press release includes forward-looking statements about CollabRx’s anticipated results that involve risks and uncertainties. Some of the information contained in this press release, including, but not limited to, statements as to industry trends and CollabRx’s plans, objectives, expectations and strategy for its business, contains forward-looking statements that are subject to risks and uncertainties that could cause actual results or events to differ materially from those expressed or implied by such forward-looking statements. Any statements that are not statements of historical fact are forward-looking statements. When used, the words “believe,” “plan,” “intend,” “anticipate,” “target,” “estimate,” “expect” and the like, and/or future tense or conditional constructions (“will,” “may,” “could,” “should,” etc.), or similar expressions, identify certain of these forward-looking statements. Important factors which could cause actual results to differ materially from those in the forward-looking statements are detailed in filings made by CollabRx with the Securities and Exchange Commission. CollabRx undertakes no obligation to update or revise any such forward-looking statements to reflect subsequent events or circumstances.

CONTACT: CollabRx Contacts:
         Thomas R. Mika, CEO
         CollabRx, Inc.
         415-248-5350

         Robert Ferri Partners, LLC
         Robert Ferri
         (415) 575-1589 (direct)
         robert.ferri@robertferri.com

         OncoDNA Contacts
         Jean-Pol Detiffe, CEO
         OncoDNA SA
         +3271347899
         jp.detiffe@oncodna.com